TICKERNERD
Menu
NTHINTHIHealthcare · Biotechnology

NTHI Stock Forecast: NeOnc Technologies Holdings, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$3.26
−4.40% on the day

The 3 Wall Street analysts covering NeOnc Technologies Holdings, Inc. hold a median 12-month price target of $15 — +360.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 19 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$93.9M
Ticker Nerd rank
20 / 100
Median analyst target
$15
Analysts covering
3
Revenue$0.0
Operating income−$13.6M
Net income−$14.2M
Free cash flow−$4.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.4%
1M
−41.0%
YTD
−60.6%
1Y
−73.0%
From 52W high
−73.0%
From 52W low
+9.0%
$3
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NTHI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NeOnc Technologies Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
20 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
76
Accruals
67
Value
52
Issuance
40
Growth
33
Revisions
26
Momentum
17
Volatility
13
Quality
11

Size (76): Smaller than most of the companies we track.

Quality (11): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NTHI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NTHI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Oct 25Jan 26Apr 26Jul 26NTHIHigh $20Median $15Low $13

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $13Median $15High $20

The green dot is the last close — the median target sits +360.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 Sept 2026BTIGReiteratesBuy$15
26 May 2026BTIGReiteratesBuy$15
26 May 2026BTIGReiteratesBuy—
19 May 2026Alliance Global PartnersInitiatesBuy$13
19 May 2026Alliance Global PartnersInitiatesBuy—
18 May 2026Maxim GroupInitiatesBuy—
24 Apr 2026BTIGInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NTHI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NTHI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, NeOnc Technologies Holdings, Inc. returned −73.0% against +16.3% for the S&P 500, dividends included.

NTHI vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26NTHIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NTHI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

NeOnc Technologies Holdings, Inc. (NTHI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.0×

Cheaper than 82% of US stocks

Price / sales
2348.2×

Cheaper than 1% of US stocks

Price / book
−4.3×

Cheaper than 96% of US stocks

EV / EBITDA
−1.4×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−104418.9%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
355.0%

Higher than 99% of US stocks

Return on assets
−635.0%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

NeOnc Technologies Holdings, Inc. (NTHI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • NeOnc Technologies Holdings, Inc. has a market value of $93.9M and an enterprise value of $82.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$47.2M.

  • Free cash flow in the twelve months to 30 June 2026: −$21.7M.

  • Shares outstanding: 25.9M.

  • Trailing P/E: −1.0×; forward P/E: −3.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • NeOnc Technologies Holdings, Inc. employs 5 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

NTHI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NTHINeOnc Technologies Holdings, Inc.$93.9M
20
NRXSNeurAxis, Inc.$94.2M
60
ANIXAnixa Biosciences, Inc.$92.9M
69
GUTSFractyl Health, Inc.$95.2M
30
RLYBRallybio Corp.$90.8M
59
ATRAAtara Biotherapeutics, Inc.$97.3M
71
ICCCImmuCell Corp.$90.0M
94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NeOnc Technologies Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NTHI news & analysis

NeOnc Eliminates Major Dilution Risk as Clinical Story Accelerates

GlobeNewsWire · 17 Sept 2026positive

NeOnc Technologies redeemed all 6,000 outstanding shares of its Series A Convertible Preferred Stock for $6 million in cash, issuing zero common shares in the process. The move removes a potential dilution risk from the company's capital structure as its clinical story advances.

Why it matters — NTHI watchers would care because eliminating the convertible preferred overhang reduces the risk of future common-share dilution to existing stockholders.

NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution

GlobeNewsWire · 17 Sept 2026positive

NeOnc Technologies announced it has redeemed for cash all 6,000 outstanding shares of its Series A Convertible Preferred Stock at their aggregate stated value of $6.0 million, eliminating the related potential dilution. The company is a multi-Phase 2 clinical-stage biopharmaceutical firm developing therapies for central nervous system cancers.

Why it matters — NTHI watchers would care because redeeming the Series A Convertible Preferred Stock removes a source of potential future share dilution for existing common stockholders.

NeOnc's $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA

GlobeNewsWire · 16 Sept 2026positive

NeOnc Technologies executives added about $629,000 of personal capital to the company following positive Phase 2a results for its experimental brain-cancer therapy NEO100. The insider purchases come amid attention on the company's next steps with the FDA.

Why it matters — NTHI watchers would care because insider buying signals management confidence in the company at a time when NEO100's regulatory path is drawing increased attention.

NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results

GlobeNewsWire · 16 Sept 2026positive

NeOnc Technologies Holdings, Inc. announced that its Executive Chairman, President and CEO Amir F. and other executives invested approximately $629,000 in open-market stock purchases following positive NEO100 Phase 2a results. The announcement was made via GlobeNewsWire on September 16, 2026.

Why it matters — Insider stock purchases by company executives following favorable clinical trial results may signal confidence in the company's progress, which NTHI watchers would consider noteworthy.

Investor Determination to Beat Cancer Puts NeOnc's Novel Therapies and Patented Platform in Focus

GlobeNewsWire · 15 Sept 2026positive

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO purchased an additional 37,000 shares of company common stock, following a $15 financing with healthcare-focused institutions. The move highlights the CEO's continued investment in the company's novel therapies and patented platform.

Why it matters — An NTHI watcher would note that the CEO's additional share purchase signals insider confidence following a healthcare-institutional financing round.

FAQ

Frequently asked questions about NTHI stock

What is the NTHI stock price forecast for 2026-2027?

The 3 Wall Street analysts covering NeOnc Technologies Holdings, Inc. have a median 12-month price target of $15, with estimates ranging from $13 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NTHI stock a buy right now?

Of the 3 analysts covering NeOnc Technologies Holdings, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NeOnc Technologies Holdings, Inc. 20 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NTHI?

As at 19 Sept 2026, NeOnc Technologies Holdings, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (76 of 100).

Will NTHI stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +360.1% from the last close, and Ticker Nerd's factor model ranks NeOnc Technologies Holdings, Inc. 20 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NTHI stock forecast for 2030?

No analyst covering NeOnc Technologies Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTHI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $20 over the next 12 months.

How has NTHI stock performed over the past year?

NeOnc Technologies Holdings, Inc. returned -73.0% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NeOnc Technologies Holdings, Inc. do?

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system cancers and other intracranial malignancies.

What is the latest news on NTHI?

The most recent item we track (GlobeNewsWire, 17 Sept 2026): "NeOnc Eliminates Major Dilution Risk as Clinical Story Accelerates". NeOnc Technologies redeemed all 6,000 outstanding shares of its Series A Convertible Preferred Stock for $6 million in cash, issuing zero common shares in the process. The move removes a potential dilution risk from the company's capital structure as its clinical story advances.

Company

About NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system cancers and other intracranial malignancies. Its current pipeline centers on NEO100, a purified form of perillyl acid being studied in Phase IIa trials, and NEO212, an oral drug candidate evaluated in Phase I/II trials for primary and secondary brain cancers, including glioblastoma, meningioma, and high-grade gliomas. The company is also developing technologies designed to improve delivery of therapeutics across the blood-brain barrier, a key challenge in treating brain diseases. NeOnc Technologies Holdings, Inc. operates within the biotechnology sector and serves the specialized oncology market with a focus on hard-to-treat brain tumors and related central nervous system conditions.

CEO Mr. Amir Farrokh Heshmatpour · 5 employees · United States · https://www.neonc.com